Anthos Therapeutics To Be Acquired by Novartis for Up To $3.1 Billion
Deal News | Feb 11, 2025 | Goodwin
Anthos Therapeutics, a biopharmaceutical company backed by Blackstone Life Sciences, is set to be acquired by Novartis for up to $3.1 billion. Founded in 2019 by Blackstone and Novartis, Anthos holds rights to abelacimab, a factor XI inhibitor aimed at preventing stroke and embolism. The deal involves a $925 million upfront payment to Anthos shareholders, with additional payments contingent on achieving regulatory and commercial milestones. The transaction is slated for completion by H1 2025, subject to regulatory approvals and conditions. Goodwin's Life Sciences and M&A teams advised Anthos in this strategic acquisition.
Sectors
- Life Sciences
- Mergers and Acquisitions (M&A)
Geography
- United States – The transaction involves U.S. company Anthos Therapeutics and requires regulatory approval under U.S. antitrust laws.
- Switzerland – Novartis, a Swiss multinational pharmaceutical company, is acquiring Anthos Therapeutics.
Industry
- Life Sciences – The article pertains to Anthos Therapeutics, a biopharmaceutical company, and Blackstone Life Sciences, focusing on medicine and medical technologies.
- Mergers and Acquisitions (M&A) – The article discusses the acquisition of Anthos Therapeutics by Novartis, highlighting a significant transaction in the industry.
Financials
- $3.1 billion – Total potential amount for the acquisition of Anthos Therapeutics by Novartis.
- $925 million – Upfront payment to Anthos shareholders upon closing of the transaction.
- $12 billion – Assets under management by Blackstone Life Sciences.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Anthos Therapeutics | Target Company | Company | A clinical-stage biopharmaceutical company with global rights to develop, manufacture, and commercialize abelacimab. |
| Novartis | Bidding Company | Company | A Swiss multinational pharmaceutical company acquiring Anthos Therapeutics. |
| Blackstone Life Sciences | Selling Company | Company | The majority investor in Anthos Therapeutics, an investment platform in the life sciences sector. |
| Goodwin | Legal Advisor | Company | Provided legal advice to Anthos Therapeutics in the acquisition agreement. |
| Richard Hoffman | Legal Advisor | Person | Part of the Goodwin team advising on the deal. |
| Lisa Haddad | Legal Advisor | Person | Part of the Goodwin team advising on the deal. |
| Katherine Baudistel | Legal Advisor | Person | Part of the Goodwin team advising on the deal. |
| Stuart Cable | Legal Advisor | Person | Part of the Goodwin team advising on the deal. |
| Andrew Schipper | Legal Advisor | Person | Part of the Goodwin team advising on the deal. |